RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability

被引：0

作者：

Ernest Nadal

Hidehito Horinouchi

Jin-Yuan Shih

Kazuhiko Nakagawa

Martin Reck

Edward B. Garon

Yu-Feng Wei

Jens Kollmeier

Bente Frimodt-Moller

Emily Barrett

Olga Lipkovich

Carla Visseren-Grul

Silvia Novello

机构：

[1] Catalan Institute of Oncology,Faculty of Medicine

[2] IDIBELL,Department of Oncology

[3] L’Hospitalet,undefined

[4] National Cancer Center Hospital,undefined

[5] National Taiwan University Hospital,undefined

[6] Kindai University,undefined

[7] LungenClinic,undefined

[8] Airway Research Center North,undefined

[9] German Center for Lung Research,undefined

[10] David Geffen School of Medicine at UCLA/Translational Research in Oncology-US Network,undefined

[11] E-Da Cancer Hospital,undefined

[12] I-Shou University,undefined

[13] Helios Klinikum Emil von Behring,undefined

[14] Eli Lilly and Company,undefined

[15] Eli Lilly and Company,undefined

[16] Eli Lilly and Company,undefined

[17] Lilly Oncology,undefined

[18] University of Turin,undefined

[19] A.O.U. San Luigi Gonzaga,undefined

来源：

Drug Safety | 2022年 / 45卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：45 / 64

页数：19

共 50 条

[1] RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability
Nadal, Ernest
Horinouchi, Hidehito
Shih, Jin-Yuan
Nakagawa, Kazuhiko
Reck, Martin
Garon, Edward B.
Wei, Yu-Feng
Kollmeier, Jens
Frimodt-Moller, Bente
Barrett, Emily
Lipkovich, Olga
Visseren-Grul, Carla
Novello, Silvia
DRUG SAFETY, 2022, 45 (01) : 45 - 64
[2] RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
Kazuhiko Nakagawa
Edward B. Garon
Ling Gao
Sophie Callies
Annamaria Zimmermann
Richard Walgren
Carla Visseren-Grul
Martin Reck
Cancer Chemotherapy and Pharmacology, 2022, 90 : 137 - 148
[3] RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship
Nakagawa, Kazuhiko
Garon, Edward B.
Gao, Ling
Callies, Sophie
Zimmermann, Annamaria
Walgren, Richard
Visseren-Grul, Carla
Reck, Martin
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 90 (02) : 137 - 148
[4] Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results
Garon, E. B.
Reck, M.
Nishio, K.
Heymach, J. V.
Nishio, M.
Novello, S.
Paz-Ares, L.
Popat, S.
Aix, S. Ponce
Graham, H.
Butts, B. D.
Visseren-Grul, C.
ESMO OPEN, 2023, 8 (04)
[5] Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset
Nishio, Kazuto
Seto, Takashi
Nishio, Makoto
Reck, Martin
Garon, Edward B.
Sakai, Kazuko
Goto, Koichi
Kato, Terufumi
Nakanishi, Yoichi
Takahashi, Toshiaki
Yamamoto, Nobuyuki
Kiura, Katsuyuki
Ohe, Yuichiro
Tamura, Tomohide
Visseren-Grul, Carla
Frimodt-Moller, Bente
Hozak, Rebecca R.
JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (06):
[6] Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreatedEGFR-mutated metastatic non-small-cell lung cancer
Yoh, Kiyotaka
Atagi, Shinji
Reck, Martin
Garon, Edward B.
Ponce Aix, Santiago
Moro-Sibilot, Denis
Winfree, Katherine B.
Frimodt-Moller, Bente
Zimmermann, Annamaria
Visseren-Grul, Carla
Nakagawa, Kazuhiko
CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (10) : 1667 - 1675
[7] Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer
Garon, Edward B.
Reck, Martin
Paz-Ares, Luis
Ponce, Santiago
Corral Jaime, Jesus
Juan, Oscar
Nadal, Ernest
Lee, Pablo
Dalal, Rita
Liu, Jingyi
He, Shuang
Treat, Joseph
Nakagawa, Kazuhiko
CLINICAL LUNG CANCER, 2017, 18 (01) : 96 - 99
[8] RELAY, ramucirumab plus erlotinib (RAM plus ERL) versus placebo plus erlotinib (P plus ERL) in untreated EGFR mutated metastatic non-small cell lung cancer (NSCLC): Exposure-response relationship
Nakagawa, K.
Garon, E.
Gao, L.
Callies, S.
Zimmermann, A.
Walgren, R.
Visseren-Grul, C.
Reck, M.
ANNALS OF ONCOLOGY, 2020, 31 : S839 - S840
[9] Ramucirumab or placebo plus erlotinib inEGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY
Nishio, Makoto
Seto, Takashi
Reck, Martin
Garon, Edward B.
Chiu, Chao-Hua
Yoh, Kiyotaka
Imamura, Fumio
Park, Keunchil
Shih, Jin-Yuan
Visseren-Grul, Carla
Frimodt-Moller, Bente
Zimmermann, Annamaria
Homma, Gosuke
Enatsu, Sotaro
Nakagawa, Kazuhiko
CANCER SCIENCE, 2020, 111 (12) : 4510 - 4525
[10] Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study
Chiu, Chao-Hua
Lin, Meng-Chih
Wei, Yu-Feng
Chang, Gee-Chen
Su, Wu-Chou
Hsia, Te-Chun
Su, Jian
Wang, Anne Kuei-Fang
Jen, Min-Hua
Puri, Tarun
Shih, Jin-Yuan
TARGETED ONCOLOGY, 2023, 18 (04) : 505 - 515

← 1 2 3 4 5 →